Novo Nordisk at this time offered knowledge from the STEER real-world research of proof gathered from precise affected person experiences on the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The STEER research investigated the danger of main adversarial cardiovascular occasions (MACE) with Wegovy® (semaglutide 2.4 mg) in contrast with tirzepatide therapy in folks with obese or weight problems and established CVD with out diabetes.1
In contrast with tirzepatide, Wegovy® confirmed a major 57% better threat discount for coronary heart assault, stroke and cardiovascular-related loss of life or loss of life from any trigger, in folks with obese or weight problems and CVD, who didn’t have any gaps of their therapy lasting greater than 30 days. There have been 15 (0.1%) of those cardiovascular occasions recorded with Wegovy®, and 39 occasions (0.4%) had been recorded with tirzepatide. The typical follow-up period was 3.8 months for the Wegovy® group and 4.3 months for the tirzepatide group.1
In all handled folks, no matter any gaps of their therapy, Wegovy® confirmed a major 29% threat discount for coronary heart assault, stroke and loss of life from any trigger in contrast with tirzepatide (over a mean follow-up of 8.3 months for Wegovy® and eight.6 months for tirzepatide).1
“Our landmark trial, SELECT, confirmed that Wegovy® is related to a major 20% threat discount of cardiovascular occasions, backed up with even better threat reductions within the real-world research SCORE and STEER. The outcomes are clear – STEER demonstrates that Wegovy® cuts the danger of coronary heart assault, stroke or loss of life by 57% in comparison with tirzepatide,” mentioned Ludovic Helfgott, govt vp and head of Product & Portfolio Technique at Novo Nordisk. “This knowledge confirms that semaglutide stands aside as the one out there GLP-1-based medicine with confirmed cardiovascular advantages for folks residing with weight problems and heart problems, with out diabetes.”
Moreover, in all handled folks, no matter any gaps of their therapy, folks handled with Wegovy® skilled fewer occasions of coronary heart assault, stroke and cardiovascular-related loss of life than folks handled with tirzepatide.1
About weight problems and heart problems
Yearly, virtually 21 million folks die from CVD, which is the main reason for incapacity and loss of life worldwide.2 Weight problems immediately results in cardiovascular morbidity, mortality and hospitalisation.3,4 Whereas cardiovascular mortality has decreased over the previous 20 years, obesity-related cardiovascular deaths have elevated considerably, with two in three obesity-related deaths being linked to CVD.5,6
In regards to the real-world STEER research
Actual-world research of proof gathered from precise affected person experiences can complement randomised management trials, that are the gold normal for evaluating the security and efficacy of a therapy.7 STEER was a retrospective, observational real-world research, evaluating the efficacy of Wegovy® (semaglutide 2.4 mg) versus tirzepatide for the prevention of MACE in US adults with obese or weight problems and established CVD with no prior historical past of diabetes, with a main consequence measure of revised 5-point MACE (coronary heart assault, stroke, hospitalisation for coronary heart failure, coronary revascularisation, and loss of life from any trigger) and revised 3-point MACE (coronary heart assault, stroke and loss of life from any trigger). Non-revised 5-point and 3-point MACE was additionally studied, which included cardiovascular-related loss of life slightly than loss of life from any trigger.1
The research included folks from the US Komodo Analysis database (1 January 2016 to 31 January 2025) aged ≥45 years and began therapy with Wegovy® or tirzepatide on or after 13 Could 2022. Every therapy group comprised 10,625 folks. To make sure each teams had been comparable, researchers used propensity rating matching to match Wegovy® customers and tirzepatide customers with comparable traits. After matching, traits had been well-balanced between the therapy teams.1
The primary evaluation included all individuals who began therapy, no matter any gaps of their remedy, whereas a sensitivity evaluation evaluated outcomes solely in individuals who didn’t have any gaps of their therapy lasting greater than 30 consecutive days.1
In regards to the SELECT trial and SCORE real-world research
SELECT was a randomised, double-blind, parallel-group, placebo-controlled trial designed to judge the efficacy of Wegovy® (semaglutide 2.4 mg) versus placebo as an adjunct to plain of look after the prevention of MACE in folks with obese or weight problems and established CVD with no prior historical past of diabetes. Folks included within the trial had been aged ≥45 years with a physique mass index (BMI) of ≥27 kg/m2.8
The first goal of the SELECT trial was to reveal the prevalence of Wegovy® in comparison with placebo with respect to lowering the incidence of 3-point MACE consisting of cardiovascular loss of life, non-fatal coronary heart assault (myocardial infarction) or non-fatal stroke.8
SCORE was a real-world research within the US that analysed MACE outcomes amongst Wegovy® (semaglutide 2.4 mg) customers and non-users in real-world medical follow, who met comparable inclusion standards as within the SELECT trial and had been aged ≥45 years with obese or weight problems and established CVD with out diabetes.9
About Wegovy®
Semaglutide 2.4 mg is marketed below the model identify Wegovy®. Within the EU, Wegovy® is indicated as an adjunct to a reduced-calorie food plan and elevated bodily exercise for weight administration in adults with a BMI of 30 kg/m2 or better (weight problems) or adults with a BMI of 27 kg/m2 or better (obese) within the presence of not less than one weight-related comorbid situation. Within the EU, Wegovy® can be indicated for paediatric sufferers aged 12 years and older with an preliminary BMI on the 95th percentile or better for age and gender (weight problems) and physique weight above 60 kg. The medical part of the label additionally consists of knowledge on Wegovy® main adversarial cardiovascular occasions (MACE) threat discount, enhancements in coronary heart failure with preserved ejection fraction (HFpEF)-related signs and bodily perform, in addition to ache discount associated to knee osteoarthritis.10
Within the US, Wegovy® is indicated together with a lowered calorie food plan and elevated bodily exercise to scale back the danger of MACE in adults with established heart problems and both weight problems or obese, in addition to to scale back extra physique weight and preserve weight discount long run in paediatric sufferers aged 12 years and older with weight problems and in adults with weight problems or with obese within the presence of not less than one weight-related comorbid situation.11